Roche signs deal with Eleven Bio
Roche has bagged access to Eleven Biotherapeutics’ eye disease candidate EBI-031 in a deal worth around $270 million.
Read More
Tag: Eleven Biotherapeutics
- Transgene completes randomisation in phase 2 trial of tg4050
- Bayer wins MHRA approval for Kerendia in heart failure
- Oxford BioTherapeutics signs collaboration with Bristol Myers Squibb
- Kainova expands DT 7012 trial into Europe
- Amgen reports positive phase 3 results for subcutaneous TEPEZZA in thyroid eye disease
